These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25520521)

  • 21. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary PCSK9 variants: A new database.
    Leigh SE; Leren TP; Humphries SE
    Atherosclerosis; 2009 Mar; 203(1):32-3. PubMed ID: 19249440
    [No Abstract]   [Full Text] [Related]  

  • 23. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
    Leren TP
    Clin Genet; 2004 May; 65(5):419-22. PubMed ID: 15099351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent in vivo epigenetic silencing of Pcsk9.
    Gengaro IR; Qi LS
    Cell Res; 2024 Sep; 34(9):607-608. PubMed ID: 38565654
    [No Abstract]   [Full Text] [Related]  

  • 26. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
    Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
    Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys.
    Wang Y; Ma M; Wang JA; Daugherty A; Lu HS
    Curr Opin Lipidol; 2019 Apr; 30(2):154-155. PubMed ID: 30844857
    [No Abstract]   [Full Text] [Related]  

  • 30. Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'.
    Burkhardt R
    Curr Opin Lipidol; 2015 Oct; 26(5):468-9. PubMed ID: 26339769
    [No Abstract]   [Full Text] [Related]  

  • 31. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot.
    Fazio S; Tavori H
    Circ Res; 2014 Aug; 115(5):472-4. PubMed ID: 25124321
    [No Abstract]   [Full Text] [Related]  

  • 34. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
    Shen L; Peng HC; Nees SN; Zhao SP; Xu DY
    FEBS Lett; 2013 May; 587(9):1271-4. PubMed ID: 23499248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form.
    Rocha CS; Wiklander OP; Larsson L; Moreno PM; Parini P; Lundin KE; Smith CI
    J Mol Cell Cardiol; 2015 May; 82():186-93. PubMed ID: 25791168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM
    J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The genetic spectrum of familial hypercholesterolemia in south-eastern Poland.
    Sharifi M; Walus-Miarka M; Idzior-Waluś B; Malecki MT; Sanak M; Whittall R; Li KW; Futema M; Humphries SE
    Metabolism; 2016 Mar; 65(3):48-53. PubMed ID: 26892515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.
    Al-Mashhadi RH; Sørensen CB; Kragh PM; Christoffersen C; Mortensen MB; Tolbod LP; Thim T; Du Y; Li J; Liu Y; Moldt B; Schmidt M; Vajta G; Larsen T; Purup S; Bolund L; Nielsen LB; Callesen H; Falk E; Mikkelsen JG; Bentzon JF
    Sci Transl Med; 2013 Jan; 5(166):166ra1. PubMed ID: 23283366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond LDL cholesterol, a new role for PCSK9.
    Akram ON; Bernier A; Petrides F; Wong G; Lambert G
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
    Levenson AE; Haas ME; Miao J; Brown RJ; de Ferranti SD; Muniyappa R; Biddinger SB
    Endocrinology; 2016 Apr; 157(4):1421-9. PubMed ID: 26824363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.